|
1. A method of treating or preventing a disease or condition in a subject by administration of a recombinant retroviral vector with defective retroviral integration activity, comprising administering to the subject a recombinant retroviral vector comprising a first nucleic acid sequence encoding a mutant integrase and a second nucleic acid sequence encoding at least one payload comprising an antigen, said mutant integrase, when compared to a wild-type integrase having a sequence of SEQ ID NO: 1, comprises at least one mutation in a Mg2+ binding motif of a catalytic core domain selected from the group consisting of D125A, D184A, and E220A; wherein the recombinant retroviral vector has defective retroviral integration activity as compared to a recombinant retroviral vector comprising the wild-type integrase, wherein the at least one payload is expressed in the subject for at least three days, wherein the recombinant retroviral vector is a recombinant murine leukemia virus (MLV), and wherein the antigen induces an immune response in the subject, thereby treating or preventing the disease or condition in the subject.
|